{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'The secondary endpoints of change from baseline to Week 16 in NPS, NC, and TSS will be', 'analyzed with MMRM using an REML approach, employing a similar methodological approach', 'as the analysis of the primary endpoint. The analysis of change from baseline to Week 16 in NPS', 'will be conducted in the CRSwNP stratum, with the fixed, categorical effect for randomization', 'strata in the MMRM model defined by presence of NP and comorbid asthma (ie, CRSwNP with', 'comorbid asthma and CRSwNP without comorbid asthma). For NC and TSS, the average of the', 'scores recorded during the last 7 days before a given visit (14 scores, including the morning of', 'the visit) will be used to determine the value for that visit.', 'The secondary endpoint of time to first response (> 1 point improvement from baseline) in NPS', 'will be conducted in the CRSwNP stratum and will be analyzed using a stratified Cox', 'proportional hazards model, stratified on the basis of the presence or absence of comorbid', 'asthma, adjusted for country, baseline NPS, and treatment group. Subjects without a response', 'in NPS will be censored at their last NPS assessment. The secondary endpoint of time to first', 'CRS exacerbation will be analyzed using a stratified Cox proportional hazards model, stratified', 'on the basis of the presence or absence of NP and comorbid asthma (ie, CRSwNP with comorbid', 'asthma, CRSwNP without comorbid asthma, and CRSsNP), adjusted for country and treatment', 'group. Subjects without a CRS exacerbation will be censored at their last assessment for CRS', 'exacerbation. Kaplan-Meier estimates and curves will be provided for both time to first response', 'in NPS and time to first CRS exacerbation.', '9.4.2.', 'Safety Analyses', 'Safety and tolerability will be examined based on AEs, clinical laboratory results, vital signs,', 'and 12-lead ECG assessments.', 'Safety analyses will be focused on TEAEs, defined as AEs with onset on or after the first dose of', 'IP. The incidence of AEs and SAEs will be summarized by treatment group, including the', 'incidence by system organ class and preferred term. In addition, the incidence of AEs by', 'severity, the incidence of treatment-related AEs, and the incidence of AEs leading to study drug', 'discontinuation/study withdrawal will be summarized by system organ class and preferred term.', 'Laboratory, vital signs, and ECG data will be analyzed by treatment group using summary', 'statistics for actual values of and change from baseline in continuous parameters. The number', 'and frequency of subjects with pre-defined abnormalities considered clinically significant will be', 'presented. For laboratory parameters, the number and frequency of subjects with shifts from', 'baseline to low or high values based on normal ranges will also be presented.', '9.5.', 'Interim Analyses', 'No formal interim analyses are planned.', 'See Section 6.3.3 regarding unblinded analyses to be performed by Sponsor individuals not', 'directly involved in the conduct of the study to inform further development of GB001.', '48', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.', 'APPENDICES', '10.1.', 'Appendix 1: Regulatory, Ethical, and Study Oversight', 'Considerations (site responsibilities)', '10.1.1.', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with the following:', '- Consensus ethical principles derived from international guidelines including the', 'Declaration of Helsinki and Council for International Organizations of Medical', 'Sciences (CIOMS) International Ethical Guidelines', '- Applicable ICH Good Clinical Practice (GCP) Guidelines', '- Applicable laws and regulations', 'The protocol, protocol amendments, ICF, IB, Diary and other relevant documents', '(eg, advertisements) must be submitted to an IRB/IEC by the investigator and', 'reviewed and approved by the IRB/IEC before the study is initiated.', 'Any amendments to the protocol will require IRB/IEC approval before', 'implementation of changes made to the study design, except for changes necessary', 'to eliminate an immediate hazard to study subjects.', 'The investigator will be responsible for the following:', '- Providing written summaries of the status of the study to the IRB/IEC annually', 'or more frequently in accordance with the requirements, policies, and procedures', 'established by the IRB/IEC', '- Notifying the IRB/IEC of SAEs or other significant safety findings as required by', 'IRB/IEC procedures', '- Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 CFR (or equivalent for non-IND sites), ICH guidelines, the', 'IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all', 'other applicable local regulations', '10.1.2.', 'Informed Consent Process', 'The investigator or his/her representative will explain the nature of the study to the', 'subject or his/her legally authorized representative and answer all questions regarding', 'the study.', 'Subjects must be informed that their participation is voluntary. Subjects or their', 'legally authorized representative will be required to sign a statement of informed', 'consent that meets the requirements of 21 CFR 50 (or equivalent for non-IND sites),', 'local regulations, ICH guidelines, Health Insurance Portability and Accountability', 'Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.', '49', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}